Erlotinib-based Targeted Dual-agent Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer: A Meta-analysis of 13 Randomized Controlled Trials.

CONCLUSIONS: Compared with erlotinib alone, erlotinib-based targeted dual-agent showed minimal magnitude of improvement in PFS but did not improve OS. The role of erlotinib-based combination in previously treated patients with NSCLC seemed insignificant. PMID: 27479336 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research